Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

NCT ID: NCT00930943

Last Updated: 2023-05-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-05-31
• Study Completion Date: 2009-11-30

Brief Summary

The purpose of the study is to determine whether extended-release oxymorphone hydrochloride taken orally with a high-fat meal, generating an approximately 50% higher Cmax, impacts cognitive functioning, using Cambridge Neuropsychological Test Automated Battery (CANTAB) tests, to a greater extent than when taking under conditions of fasting.

Detailed Description

Oxymorphone 40 mg ER affects cognitive performance similarly within 3 hours post dose, whether given on an empty stomach or after a high-fat meal, suggesting that the altered pharmacokinetics, fed versus fasting and as described above, is not relevant for the medication's impact on cognition. Hence, the direction for oxymorphone ER to be dosed at least 1 hour before or 2 hours after eating, at least from a cognitive perspective, may be without merit.

Conditions

Chronic Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Oxymorphone ER 40 mg fed

Participants received 40 mg oxymorphone ER after a high-fat meal of approximately 1,010 kCal

Group Type: EXPERIMENTAL

Oxymorphone ER

Intervention Type: DRUG

40 mg qd twice

Oxymorphone ER 40 mg fasting

Participants received 40 mg oxymorphone ER after fasting for 8-12 hours

Group Type: EXPERIMENTAL

Oxymorphone ER

Intervention Type: DRUG

40 mg qd twice

Interventions

Oxymorphone ER

40 mg qd twice

Intervention Type: DRUG

Other Intervention Names

Opana ER

Eligibility Criteria

Inclusion Criteria

1. Man or woman, 18-65 years of age, inclusive

2. Able to provide informed consent and comply with all study procedures

3. Women of childbearing potential with a negative urine pregnancy test at screening and on adequate contraception

4. Chronic, non-malignant, painful condition, treated with long-acting opioid (methadone, OxyContin®, MS (Morphine Sulfate) Contin®, Kadian®, Avinza®, Fentanyl®, Opana® ER)

5. Opioid treatment for at least 3 months prior to screening at a minimum dose of 90 mg of morphine equivalents per day or 50 mcg of the fentanyl transdermal patch

6. Dose of opioid treatment stable for at least 1 week prior to screening and expected to be stable from screening through end of second testing

7. Weight at screening 100-300 pounds, inclusive

Exclusion Criteria

1. Pregnant or breastfeeding

2. Gastrointestinal disorder or S/P gastrointestinal surgery impacting absorption of study medication (delayed gastric emptying, partial or complete gastrectomy)

3. Alcohol or substance abuse within 2 years of screening

4. Consumption of alcohol within 24 hours of a screening or testing visit

5. Consumption of xanthine-containing beverages (coffee, tea, coke) on the morning of a screening or testing visit

6. Impaired kidney or liver function (transaminase levels more than 3 times elevated; estimated creatinine clearance less than 50 mL/min)

7. Epworth sleepiness scale (ESS) score 16 or higher at screening

8. Medically concerning hypertension (≥ 160/100) or unstable cardiovascular illness

9. Any clinically significant illness that would interfere with study participation or put the subject at risk

10. Exposure to investigational medication within 30 days of screening

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MedVadis Research Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Egilius LH Spierings, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

MedVadis Research Corporation

Locations

MedVadis Research Corporation

Wellesley Hills, Massachusetts, United States

Countries

United States

References

Spierings EL, Volkerts ER, Heitland I, Thomson H. A randomized, rater-blinded, crossover study of the effects of oxymorphone extended release, fed versus fasting, on cognitive performance as tested with CANTAB in opioid-tolerant subjects. Pain Med. 2014 Feb;15(2):264-71. doi: 10.1111/pme.12307. Epub 2013 Dec 11.

Reference Type: RESULT

PMID: 24330343 (View on PubMed)

Other Identifiers

2009-133A

Identifier Type: -

Identifier Source: org_study_id